Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats

Acta Pharmacologica Sinica

Volumn 33, Issue 11, 2012, Pages 1379-1386

  Li, Xin Gang ^b   Li, Liang ^b   Zhou, Xuan ^b   Chen, Ye ^b   Ren, Yu Peng ^b   Zhou, Tian Yan ^a,b   Lu, Wei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

effect compartment; Exenatide; glucose; indirect response model; insulin; NONMEM; pharmacokinetic pharmacodynamic; type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIABETES CONTROL; DRUG ABSORPTION; DRUG BLOOD LEVEL; GLUCOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MODELS, BIOLOGICAL; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; VENOMS;

EID: 84865360479     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.33     Document Type: Article

References (22)

1. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the patho-genesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787-94.
2. Barnett AH. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol (Oxf) 2009; 70:343-53.
3. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26:2929-40.
4. Parkes DG, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Develop Res 2001; 53:260-7.
5. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-30.
6. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001; 50:583-9.
7. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49:741-8.
8. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-Amide an antagonist at the glucagon-like peptide 1-(7-36)-Amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268:19650-5.
9. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al. Glucose-lowering and insulin-sensitizing actions of exendin-4-studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 1999; 48:1026-34.
10. Mager DE, Abernethy DR, Egan JM, Elahi D. Exendin-4 pharma-codynamics: insights from the hyperglycemic clamp technique. J Pharmacol Exp Ther 2004; 311:830-5.
11. Jusko WJ, Gao W. Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic goto-kakizaki rats. J Pharmacol Exp Ther 2011; 336:881-90.
12. Xing XH, Zhang ZM, Hu XZ, Wu RQ, Xu C. Antidiabetic effects of Artemisia sphaerocephala Krasch. gum, a novel food additive in China, on streptozotocin-induced type 2 diabetic rats. J Ethno pharmacol 2009; 125:410-6.
13. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, et al. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 2008; 356:231-8.
14. Schmitz O, Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004; 53:2397-403.
15. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics-Application to D-tubocurarine. Clin Pharmacol Ther 1979; 25:358-71.
16. Miyazaki M, Mukai H, Iwanaga K, Morimoto K, Kakemi M. Pharma-cokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability. J Pharm Pharmacol 2001; 53:1235-46.
17. Woodworth JR, Howey DC, Bowsher RR. Establishment of time-Action profles for regular and Nph insulin using pharmacodynamic modeling. Diabetes Care 1994; 17:64-9.
18. Gopalakrishnan M, Suarez S, Hickey AJ, Gobburu JV. Population pharmacokinetic-pharmaco-dynamic modeling of subcutaneous and pulmonary insulin in rats. J Pharmacokinet Pharmacodyn 2005; 32:485-500.
19. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur J Pharm Sci 2003; 19:141-50.
20. Kwon KI, Yun HY, Park HC, Kang W. Pharmacokinetic and pharma-codynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans. J Clin Pharm Ther 2006; 31:469-76.
21. Lin SS, Chien YW. Pharmacokinetic-pharmacodynamic modelling of insulin: comparison of indirect pharmacodynamic response with effect-compartment link models. J Pharm Pharmacol 2002; 54:791-800.
22. Perez-Tilve D, Gonzalez-Matias L, Aulinger BA, Alvarez-Crespo M, Gil-Lozano M, Alvarez E, et al. Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab 2010; 298: E1088-9 6.